ArticleThe Journal of biological chemistry2016
Targeting a Novel RNA-Protein Interaction for Therapeutic Intervention of Hantavirus Disease.
Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- RNA binding proteins (RBPs) on genetic stability and diseases.Global medical genetics · 2025Review
- Modulations in the host cell proteome by the hantavirus nucleocapsid protein.PLoS pathogens · 2024Article
- SARS-CoV-2 Nucleocapsid Protein Is a Potential Therapeutic Target for Anticoronavirus Drug Discovery.Microbiology spectrum · 2023Article
- Hantavirus Induced Kidney Disease.Frontiers in medicine · 2021Review
- Crimean-Congo hemorrhagic fever virus nucleocapsid protein harbors distinct RNA-binding sites in the stalk and head domains.The Journal of biological chemistry · 2019Article
- Hantavirus RdRp Requires a Host Cell Factor for Cap Snatching.Journal of virology · 2019Article
- Vaccines and Therapeutics Against Hantaviruses.Frontiers in microbiology · 2019Review
- RNA Binding Protein RBM38 Regulates Expression of the 11-Kilodalton Protein of Parvovirus B19, Which Facilitates Viral DNA Replication.Journal of virology · 2018Article
- The nucleocapsid protein of hantaviruses: much more than a genome-wrapping protein.Virus genes · 2018Review
- Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Augments mRNA Translation.Journal of virology · 2017Article
- Development of High-Throughput Screening Assay for Antihantaviral Therapeutics.SLAS discovery : advancing life sciences R & D · 2017Article
- Phosphorylated STAT5 directly facilitates parvovirus B19 DNA replication in human erythroid progenitors through interaction with the MCM complex.PLoS pathogens · 2017Article
- Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.Journal of microbiology (Seoul, Korea) · 2017Review
- Crimean-Congo hemorrhagic fever virus nucleocapsid protein has dual RNA binding modes.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
An evolutionarily conserved sequence at the 5' terminus of hantaviral genomic RNA plays an important role in viral transcription initiation and packaging of the viral genome into viral nucleocapsids. Interaction of viral nucleocapsid protein (N) with this conserved sequence facilitates mRNA translation by a unique N-mediated translation strategy. Whereas this evolutionarily conserved sequence facilitates virus replication with the assistance of N in eukaryotic hosts having multifaceted antiviral defense, we demonstrate its interaction with N presents a novel target for therapeutic intervention of hantavirus disease. Using a high throughput screening approach, we identified three lead inhibitors that bind and induce structural perturbations in N. The inhibitors interrupt N-RNA interaction and abrogate both viral genomic RNA synthesis and N-mediated translation strategy without affecting the canonical translation machinery of the host cell. The inhibitors are well tolerated by cells and inhibit hantavirus replication with the same potency as ribavarin, a commercially available antiviral. We report the identification of a unique chemical scaffold that disrupts a critical RNA-protein interaction in hantaviruses and holds promise for the development of the first anti-hantaviral therapeutic with broad spectrum antiviral activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.